EGF-R POSITIVE NON-SMALL CELL LUNG CANCER
Clinical trials for EGF-R POSITIVE NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new EGF-R POSITIVE NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for EGF-R POSITIVE NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets tough cancers: early trial underway
Disease control OngoingThis study tests an experimental oral drug called silevertinib (BDTX-1535) in about 200 adults with advanced non-small cell lung cancer or glioblastoma, a type of brain cancer. The drug is designed to block specific EGFR mutations that help these cancers grow. The trial has two p…
Matched conditions: EGF-R POSITIVE NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Black Diamond Therapeutics, Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New hope for rare lung cancer mutations? dacomitinib under study
Disease control OngoingThis phase 2 trial is testing the targeted drug dacomitinib in 30 people with advanced non-small cell lung cancer that has uncommon EGFR mutations. Participants take a daily pill until their cancer worsens or side effects become too severe. The study aims to see how well the drug…
Matched conditions: EGF-R POSITIVE NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jun 26, 2026 15:07 UTC